Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 262

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 262
---
 $3.4 million, $2.7 million and $0.7 million, respectively. The carrying value of the Stendra® product, Timm Medical product, and PTV product as of December 31, 2023, were $4.9 million, $3.2 million and $0.9 million, respectively. During the nine months ended September 30, 2024, and 2023, respectively, the Company recorded $2.1 million and $2.5 million of amortization expense. During the three months ended September 30, 2024, and 2023, respectively, the Company recorded $0.7 million and $0.8 million of amortization expense. 7) Accrued Expenses Accrued expenses are comprised of the following:

| ​                         | ​ 
 ​ | ​ |                  ​ 
 September 30, 2024 | ​ | ​ |                 ​ 
 December 31, 2023 |
|:--------------------------|:--|:--|-------------------:|:--|:--|------------------:|
| Accrued product returns   | ​ | $ |          5,299,261 | ​ | $ |         4,178,176 |
| Accrued contract rebates  | ​ |   |             96,465 | ​ | ​ |           128,562 |
| Due to 3PL/Wholesalers    | ​ |   |             62,284 | ​ | ​ |            75,727 |
| Accrued bonuses           | ​ | ​ |            501,988 | ​ | ​ |           665,184 |
| Accrued professional fees | ​ |   |                  — | ​ | ​ |            15,000 |
| Accrued R&D fees          | ​ | ​ |            354,908 | ​ | ​ |           100,668 |
| Other accrued expenses    | ​ |   |            224,465 | ​ | ​ |           196,760 |
| Total accrued expenses    | ​ | $ |          6,539,371 | ​ | $ |         5,360,077 |

8) Debt Promissory Note In connection with the Settlement Agreement entered into with Vivus (see Note 13), Petros executed an interest-bearing promissory note (the “Note”) in favor of Vivus in the principal amount of $10,201,758. The